Hemostemix to Attend DFCon San Antonio and Closed its Private Placement

Core Insights - Hemostemix is participating in DFCon 2025, a leading conference focused on diabetic limb preservation, showcasing its innovative treatment VesCell, which has shown significant clinical outcomes in limb preservation and mortality rates [1][5] - The company has completed a private placement raising $518,440, adding to a previous closing of 4,193,000 units, each priced at $0.11, with warrants allowing for additional shares at $0.15 [2] Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a World Economic Forum Technology Pioneer, and has developed the VesCell therapy [3] - The company has conducted seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed journals, demonstrating the safety and efficacy of VesCell for various cardiovascular conditions [3][5] Clinical Results - In a Phase II clinical trial for chronic limb threatening ischemia, Hemostemix reported a 0% mortality rate and 83% limb preservation over 4.5 years, significantly better than the 50% mortality rate typically seen in this patient population [1][5] - The treatment group showed a dramatic reduction in ulcer size from a mean of 146 mm² to 0.48 mm² within three months, while the placebo group did not exhibit significant changes [1]